Skip to main content
SpringerLink
Log in

Pirtobrutinib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Pirtobrutinib (JaypircaTM), a highly selective, non-covalent, reversible Bruton’s tyrosine kinase (BTK) inhibitor, is being developed by Eli Lilly and Company (Lilly) for the treatment of B-cell leukemias and lymphomas. In January 2023, pirtobrutinib was approved in the USA under the Accelerated Approval pathway for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This article summarizes the milestones in the development of pirtobrutinib leading to this first approval for the treatment of adult patients with relapsed or refractory MCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Michot JM, Ribrag V. Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors. Lancet. 2021;397(10277):855–7.

    Article  CAS  PubMed  Google Scholar 

  2. Al-Mansour M. Treatment landscape of relapsed/refractory mantle cell lymphoma: an updated review. Clin Lymphoma Myeloma Leuk. 2022;22(11):e1019–31.

    Article  CAS  PubMed  Google Scholar 

  3. Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200(2):137–49.

    Article  CAS  PubMed  Google Scholar 

  4. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901.

    Article  CAS  PubMed  Google Scholar 

  5. Coombs CC. Extended abstract: new BTKi [abstract no. EXABS-124-CLL]. In: Society of hematologic oncology 2022 annual meeting. 2022.

  6. Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood. 2022;139(5):666–77.

    Article  CAS  PubMed  Google Scholar 

  7. Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol OncolJ Hematol Oncol. 2020;13(1):1–18.

    Google Scholar 

  8. Munshi M, Liu X, Kofides A, et al. Pirtobrutinib (LOXO-305) is active and overcomes ERK related pro-survival signaling in ibrutinib resistant, BTK (Cys481) mutant expressing WM and ABC DLBCL lymphoma cells driven by activating MYD88 mutations [abstract no. 2261]. Blood. 2021;138(Suppl 1).

  9. Eli Lilly and Company. JAYPIRCATM (pirtobrutinib): US prescribing information. 2023. https://pi.lilly.com/us/jaypirca-uspi.pdf?s=pi. Accessed 31 Jan 2023.

  10. US Food & Drug Administration. FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma [media release]. 27 January 2023. https://www.fda.gov/.

  11. European Medicines Agency. Applications for new human medicines under evaluation by the CHMP: pirtobrutinib. 2022. https://www.ema.europa.eu/documents/report/applications-new-human-medicines-under-evaluation-chmp-july-2022_en.xlsx. Accessed 31 Jan 2023.

  12. Innovent Biologics Inc. Innovent and Lilly expand strategic partnership in oncology [media release]. 27 March 2022. http://www.innoventbio.com.

  13. Eli Lilly and Company, Loxo Oncology Inc. Lilly completes acquisition of Loxo Oncology [media release]. 15 Feb 2019. www.lilly.com.

  14. Loxo Oncology. Loxo Oncology announces acquisition of highly selective, reversible BTK inhibitor program [media release]. 31 July 2017. http://www.loxooncology.com.

  15. Brandhuber B, Gomez E, Smith S, et al. LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors [abstract no. CLL-200]. Clin Lymphoma Myeloma Leuk. 2018;18 (Suppl 1):S216.

  16. Gomez EB, Ebata K, Randeria HS, et al. Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor. Blood. 2023. https://doi.org/10.1182/blood.2022018674.

    Article  PubMed  Google Scholar 

  17. Aslan B, Kismali G, Iles LR, et al. Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022;12(5):80.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Liu Y, Jiang C, Yan F, et al. Pirtobrutinib overcomes ibrutinib and venetoclax resistance in mantle cell lymphoma [abstract no. 1182]. Blood. 2021;138(Suppl 1).

  19. Liu Y, Yan F, Jiang VC, et al. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR T-cell therapy in aggressive mantle cell lymphoma. Haematologica. 2022. https://doi.org/10.3324/haematol.2022.282031.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wang ML, Shah NN, Jurczak W, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1/2 BRUIN study [abstract no. 4218 plus poster]. In: 64th American Society of Hematology Annual Meeting. 2022.

  21. Mato AR, Woyach JA, Brown JR, et al. Efficacy of pirtobrutinib in covalent BTK inhibitor pre-treated relapsed refractory CLL/SLL: additional patients and extended follow-up from the phase 1/2 BRUIN study [abstract no. 961 plus oral presentation]. In: 64th American Society of Hematology Annual Meeting. 2022.

  22. Palomba M, Patel MR, Eyre TA, et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenström macroglobulinemia: results from the phase 1/2 BRUIN study [abstract no. 229 plus oral presentation]. In: 64th American Society of Hematology Annual Meeting. 2022.

  23. Wierda WG, Lewis DJ, Ghia P, et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1/2 BRUIN study [abstract no. 347 plus oral presentation]. In: 64th American Society of Hematology Annual Meeting. 2022.

  24. Roeker LE, Mato AR, Brown JR, et al. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax ± rituximab in relapsed/refractory CLL: results from the BRUIN phase 1b study [abstract no P640]. HemaSphere. 2022;6(Suppl 3):1034.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Susan J. Keam

Authors
  1. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 186 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keam, S.J. Pirtobrutinib: First Approval. Drugs 83, 547–553 (2023). https://doi.org/10.1007/s40265-023-01860-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01860-1

Search

Navigation